Skip to Content

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

Mezigdomide is a potent, novel cereblon E3 ligase modulator leading to apoptosis in myeloma cells. At the same time, mezigdomide has a powerful synergy with dexamethasone. In this MEDtalk, Paul G. Richardson, Dana-Farber Cancer Institute, Boston, USA, presents the results showing that the combination of mezigdomide and dexamethasone has a manageable safety profile and promising efficacy for patients with triple-class refractory R/R multiple myeloma, including patients with prior BCMA-targeted therapies.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top